Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

Jonathan A. Bernstein(Bernstein Clinical Research Center), Mark Weinstein, M. Dawn Goodyear, Douglas Johnston(Mass General Brigham), Richard F. Lockey(University of South Florida), Alan P. Baptist(Henry Ford Health System), Maureen Watt(La Jolla Institute for Immunology), Hugo Chapdelaine, H. Henry Li, Aleena Banerji(Massachusetts General Hospital), Rafael Zaragoza-Urdaz(University of Puerto Rico System), Raffi Tachdjian(University of California, Los Angeles), Daniel Nova Estepan(Takeda (United States)), John Anderson, Stephen Betschel(University of Toronto), Paula J. Busse(Massachusetts General Hospital), Daniel Soteres(Vinmec International Hospital), Bruce L. Zuraw(University of California San Diego), Selina Gierer, Timothy Craig(Vinmec International Hospital), H. James Wedner(Washington University in St. Louis), Daniel Petroni(Allergy Asthma Research Institute), Florence Ida Hsu, Jason Raasch, Patricia Lugar, Alexander Kim, Salomé Juethner(Takeda (United States)), William R. Lumry(The University of Texas Southwestern Medical Center), Michael Manning(University of Puerto Rico System), Natalie Khutoryansky(Henry Ford Health System), Rémi Gagnon, Paul K. Keith, Jay M. Kashkin(Takeda (United States))
Advances in Therapy
June 12, 2025
Cited by 10


Related Papers